Compare Globus Medical Inc. Class A Common Stock (GMED) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Schwab US Dividend Equity ETF trades at $34 (market cap $111.61B). The key difference: Schwab US Dividend Equity ETF is far larger — about 10.9× Globus Medical Inc. Class A Common Stock's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Schwab US Dividend Equity ETF for 64 Days on average.
| GMED | SCHD | |
|---|---|---|
Market Cap | $10.25B | $111.61B |
Volume | 1,059,528 | 25,598,052 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $35.21 |
52-Week Low | $58.33 | $26.44 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SCHD trades at $33.37, up 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF's dividend-focused strategy is highlighted in recent news, with articles noting its outperformance against the S&P 500 in 2026 and its appeal for income investors. Key support and resistance cluster around $33, while RSI levels show mixed momentum signals.
Outlook remains positive for dividend growth and defensive positioning, but risks include interest rate sensitivity and potential missed gains from strict stock selection rules. Investors benefit from lower fees and rising payouts, though macroeconomic shifts could pressure yields.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
